BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations

Journal of Thoracic Oncology

Volumn 8, Issue 3, 2013, Pages 295-300

  Karachaliou, Niki ^a   Costa, Carlota ^a   Gimenez Capitan, Ana ^a   Molina Vila, Miguel Angel ^a   Bertran Alamillo, Jordi ^a   Mayo, Clara ^a   Massuti, Bartomeu ^b   Majem, Margarita ^c   Carcereny, Enric ^d   Moran, Teresa ^d   Sanchez, Jose Javier ^e   Viteri, Santiago ^a   Gasco, Amaya ^a   Wannesson, Luciano ^f   Souglakos, John ^g   Jimeno, Jose ^a   Rosell, Rafael ^a  

^a INSTITUT UNIVERSITARI DEXEUS   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^f ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^g UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Breast cancer gene 1; EGFR; Erlotinib; Isl 1 and Mec 3 domain only 4; Lin11; Non small cell lung cancer

Indexed keywords

BETA ACTIN; BRCA1 PROTEIN; C TERMINUS BINDING PROTEIN INTERACTING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; LIM DOMAIN ONLY 4 PROTEIN; MESSENGER RNA; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; DNA REPAIR; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION;

EID: 84874063584     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31827db621     Document Type: Article

References (30)

1. Petrelli F, Borgonovo K, Cabiddu M, Barni S. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials. Clin Lung Cancer 2012;13: 107-114.
2. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12: 735-742.
3. Rosell R, Carcereny E, Gervais R, et al.; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13: 239-246.
4. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, firstline study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011;29: 2866-2874.
5. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361: 947-957.
6. Mitsudomi T, Morita S, Yatabe Y, et al.; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11: 121-128.
7. Maemondo M, Inoue A, Kobayashi K, et al.; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362: 2380-2388.
8. Ma C, Wei S, Song Y. T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. J Thorac Dis 2011;3: 10-18.
9. Carter CA, Giaccone G. Treatment of nonsmall cell lung cancer: overcoming the resistance to epidermal growth factor receptor inhibitors. Curr Opin Oncol 2012;24: 123-129.
10. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
11. Su KY, Chen HY, Li KC, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol 2012;30: 433-440.
12. Postel-Vinay S, Vanhecke E, Olaussen KA, Lord CJ, Ashworth A, Soria JC. The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nat Rev Clin Oncol 2012;9: 144-155.
13. Lotti LV, Ottini L, D'Amico C, et al. Subcellular localization of the BRCA1 gene product in mitotic cells. Genes Chromosomes Cancer 2002;35: 193-203.
14. Husain A, He G, Venkatraman ES, Spriggs DR. BRCA1 upregulation is associated with repair-mediated resistance to cisdiamminedichloroplatinum (II). Cancer Res 1998;58: 1120-1123.
15. Taron M, Rosell R, Felip E, et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004;13: 2443-2449.
16. Rosell R, Skrzypski M, Jassem E, et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS ONE 2007;2:e1129.
17. Wang B. BRCA1 tumor suppressor network: focusing on its tail. Cell Biosci 2012;2: 6.
18. Rosell R, Molina MA, Costa C, et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced nonsmall- cell lung cancer patients with EGFR mutations. Clin Cancer Res 2011;17: 1160-1168.
19. Yu X, Wu LC, Bowcock AM, Aronheim A, Baer R. The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression. J Biol Chem 1998;273: 25388-25392.
20. Wong AK, Ormonde PA, Pero R, et al. Characterization of a carboxyterminal BRCA1 interacting protein. Oncogene 1998;17: 2279-2285.
21. Sum EY, O'Reilly LA, Jonas N, Lindeman GJ, Visvader JE. The LIM domain protein Lmo4 is highly expressed in proliferating mouse epithelial tissues. J Histochem Cytochem 2005;53: 475-486.
22. Kwong RA, Scarlett CJ, Kalish LH, et al. LMO4 expression in squamous cell carcinoma of the anterior tongue. Histopathology 2011;58: 477-480.
23. Sutherland KD, Visvader JE, Choong DY, Sum EY, Lindeman GJ, Campbell IG. Mutational analysis of the LMO4 gene, encoding a BRCA1-interacting protein, in breast carcinomas. Int J Cancer 2003;107: 155-158.
24. Dubin MJ, Stokes PH, Sum EY, et al. Dimerization of CtIP, a BRCA1- and CtBP-interacting protein, is mediated by an N-terminal coiled-coil motif. J Biol Chem 2004;279: 26932-26938.
25. Meloni AR, Smith EJ, Nevins Jr. A mechanism for Rb/p130-mediated transcription repression involving recruitment of the CtBP corepressor. Proc Natl Acad Sci USA 1999;96: 9574-9579.
26. Li S, Chen PL, Subramanian T, et al. Binding of CtIP to the BRCT repeats of BRCA1 involved in the transcription regulation of p21 is disrupted upon DNA damage. J Biol Chem 1999;274: 11334-11338.
27. Sum EY, Peng B, Yu X, et al. The LIM domain protein LMO4 interacts with the cofactor CtIP and the tumor suppressor BRCA1 and inhibits BRCA1 activity. J Biol Chem 2002;277: 7849-7856.
28. Rosell R, Moran T, Queralt C, et al.; Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361: 958-967.
29. Taniwaki M, Daigo Y, Ishikawa N, et al. Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer. Int J Oncol 2006;29: 567-575.
30. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359: 366-377.